Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — H.C. Wainwright 25th Annual Global Investment Conference (September 2023)
24 slides from Mayne Pharma's conference presentation, Sep 11, 2023
Slide 1: ASX Announcement: Mayne Pharma to present at H.C. Wainwright conference
ASX Announcement MAYNE PHARMA TO PRESENT AT THE H.C. WAINWRIGHT 25TH ANNUAL GLOBAL INVESTMENT CONFERENCE 11 September 2023, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) today announced that Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the H.C. Wainwri
Slide 2: Mayne Pharma Group Limited - HC Wainwright Healthcare Conference
Mayne Pharma For personal use only Group Limited ASX:MYX HC Wainwright Healthcare Conference September 11, 2023 Shawn Patrick O’Brien, CEO 1
Slide 3: Disclaimer
Disclaimer The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s Preliminary Financial Report and other market disclosures. This material is not intended to be relied upon as advice to investors or potential
Slide 4: FY23 Performance Highlights
FY23 Performance Highlights Refocused on core businesses and reset capital structure ✓ Completed sale of Metrics Contract Services and US Retail Generics for a combined sale price of US$565m For personal use only ✓ Created scale in US Women’s Health business via TXMD transaction1 ✓ Transformed balan
Slide 5: Mayne Pharma at a Glance
Mayne Pharma at a Glance Capitalising on commercial opportunities across three attractive business units For personal use only Putting the right people, products, and processes in place to address the needs of patients and drive long-term sustainable growth in each of our three segments Branded Prod
Slide 6: FY24 Outlook
FY24 Outlook Positive momentum continues into FY24 ✓ Completion and integration of FY23 transactions ✓ Another year of focused execution For personal use only ✓ All three business units delivering positive contribution margins ✓ Return Company to positive EBITDA in FY24 Women’s Health Dermatology In
Slide 7: Group Financial Overview
Group Financial Overview • Results are presented from continuing operations to exclude Metrics Contract Services (MCS) which was divested on 4 October 2022 and to exclude the US Retail Generics business (previously included in the Portfolio Products (PPD) segment) which was divested on 7 April 2023.
Slide 8: Segmental Performance
Segmental Performance Refocused business delivering improved momentum and positive contribution in 2H For personal use only Reported results (A$m) 1HFY23 2HFY23 FY23 FY22 1HFY23 2HFY23 FY23 FY22 Revenue Gross profit Portfolio Products 11.1 45.9 57.0 92.2 Portfolio Products -2.6 13.3 10.7 45.4 Brande
Slide 9: Cost adjustments delivering some results – more work to do
Cost adjustments delivering some results – more work to do ● FY23 OPEX without mitigating measures For personal use only would total $194.4M ● Cost savings focus delivers $5.8M in FY23 8
Slide 10: Reducing costs to enable investment in growth
Reducing costs to enable investment in growth ● FY23 investments: For personal use only (3.5%)* - $16.9m NEXTSTELLIS® DTC + AU FY23 costs FY23 (5.5%)* (2.0%)* FY24 added(2) reduction FY24 Further investment(3) launch reduction FY23 costs realized in process/ FY24 - $18m TXMD added(2) budgeted reduct
Slide 11: Branded Products Division (BPD) Women's Health
For personal use only Branded Products Division (BPD) Women’s Health
Slide 12: Women's Health / Branded Products Division (BPD) FY23 highlights
Women’s Health / Branded Products Division (BPD) FY23 highlights A$million 1H23 2H23 FY23 FY22 ● Segment performance reflects 2HFY23 contribution from licensed WH products as well as improved performance of NEXTSTELLIS® following Reported revenue 13.4 48.5 61.9 10.6 For personal use only re
Slide 13: Nextstellis - Net Sales Price Illustration
Nextstellis - Net Sales Price Illustration Co-pay change For personal use only Government Fes Medicaid Managed care Actions to improve NSP Co-Pay rules Co-Pay Misuse reduction Others Impacting GTN Via Rise-Rx Cash discounts Manage Care Chargebacks Chargebacks Pipeline Plus Possible ACA Impact Return
Slide 14: NEXTSTELLIS Update
NEXTSTELLIS® Update ● Monthly cycle count increased to 33,100 in July 2023 (+2.5x from July 2022) For personal use only ● Unit sales growth of 267% on FY22 – total units of 256,330 for FY23 ● Growth of prescriptions through improved commercial effectiveness and efficiency NEXTSTELLIS® monthly cycles
Slide 15: Women's health expansion portfolio update
Women’s health expansion portfolio update ● Women’s health expansion portfolio is delivering to expectation in demand units (scripts) ● Momentum building into FY24 as investment in sales and marketing is gaining traction in the menopause For personal use only including targeting specialist HCPs IMVE
Slide 16: Portfolio Products Division (PPD) Dermatology
For personal use only Portfolio Products Division (PPD) Dermatology
Slide 17: Portfolio Products Division (PPD) - Dermatology FY23 highlights
Portfolio Products Division (PPD) - Dermatology FY23 highlights For personal use only A$million 1H23 2H23 FY23 FY22 ● 2HFY23 sales reflecting improved sales as inventories normalised and pricing stabilised Reported revenue 11.1 45.9 57.0 92.2 Reported Gross Profit (2.6) 13.3 10.7 45.4 ● Con
Slide 18: Disintermediating the Pharmaceutical Value Chain
Disintermediating the Pharmaceutical Value Chain Pharmaceutical Value Chain For personal use only The pharmaceutical value chain is filled with Plan Sponsor inefficiencies and pain points • Multiple stakeholders with opposing financial interests cause inefficiencies, higher costs, lack of transparen
Slide 19: Disintermediation Strategy
Disintermediation Strategy Mayne Pharma’s unique platform spans the entire value chain, allowing for the ability to create a comprehensive, frictionless, transparent, and cost-effective experience For personal use only Why Dermatology? Why Mayne Pharma? 130 territory representatives ✓ There is great
Slide 20: International
For personal use only International
Slide 21: International FY23 highlights
International FY23 highlights ● Solid progress as new management team commenced business For personal use only improvement initiatives at Salisbury manufacturing facility including product throughput efficiency, procurement initiatives and building International business development opportunities A$
Slide 22: Strategy for Growth
Strategy for Growth Addressing the needs of patients across 3 segments while driving sustainable profitability and growth For personal use only Near term initiatives Broaden Women’s Health and Dermatology portfolios, leveraging sales infrastructure and Patients distribution platforms Continue to fin
Slide 23: Business Outlook and Priorities for FY24
Business Outlook and Priorities for FY24 ● The Company expects to complete integration of the licensed women’s health assets in FY24 with a focus on growth and improving net selling prices. The Company is pursuing a growth strategy with the expected launch of For personal use only low strength BIJUV
Slide 24: Q&A
Q&A For personal use only Mayne Pharma Group Limited ASX:MYX You deserve tomorrow. 23